


What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

**I**

wherein

n is 1 or 2;

R¹ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, -CH₂-R⁸,
 10 -C(=O)-NH-R⁷, -C(=S)-NH-R⁷, -C(=O)-O-R⁷, -S(=O)₂-R⁶, and -C(=O)-R⁵, wherein
 R⁵, R⁶, R⁷ and R⁸ are independantly selected from C₁₋₆alkyl, C₂₋₆alkenyl,
 C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl,
 C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and
 C₃₋₆heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,
 15 C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl,
 C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl used in
 defining R¹, R⁵, R⁶, R⁷ or R⁸ are optionally substituted with one or more groups
 selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-R, -C(=O)-OR,
 -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy and halogen,
 20 or disubstituted with -O-CH₂-O- to form a fused ring;

R² is selected from -H and C₁₋₆alkyl;

R³ and R⁴ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl,
 C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl,
 C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and
 25 C₃₋₆heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,
 C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl,

C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy and halogen; or R³ and R⁴ together with the nitrogen

- 5 connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen;

- 10 Ar is selected from C₆₋₁₀aryl and C₃₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₃₋₆heteroaryl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen; and

R is C₁₋₆alkyl.

- 15 2. A compound according to claim 1,

wherein n is 1 or 2;

- R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, -CH₂-R⁸, -C(=O)-NH-R⁷, -C(=S)-NH-R⁷, -S(=O)₂-R⁶, and -C(=O)-R⁵, wherein R⁵, R⁶, R⁷ and R⁸ are independantly selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, phenyl, phenyl-C₁₋₂alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₂alkyl, wherein said C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆alkyl, phenyl, phenyl-C₁₋₂alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₂alkyl used in defining R¹, R⁵, R⁶, R⁷ or R⁸ are optionally substituted with one or more groups
20 selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₃alkyl, -C(=O)-R, -C(=O)-OR, -SR, -CF₃, -CN, methoxy, ethoxy, fluoro and chloro, or disubstituted with -O-CH₂-O- to form a fused ring;

R² is selected from -H, methyl and ethyl;

- 30 R³ and R⁴ are independently selected from -H, C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, phenyl, phenyl-C₁₋₂alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl, and

C₃₋₆heteroaryl-C₁₋₂alkyl, wherein said C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, phenyl, phenyl-C₁₋₂alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₂alkyl are optionally substituted with one or more groups selected from -CHO, -NH₂, -NHR, -NR₂, C₁₋₃alkyl, -C(=O)-OR, -CF₃, -CN, methoxy, ethoxy, fluoro and chloro; or R³ and R⁴ together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted with one or more groups selected from benzyl, -CHO, C₁₋₃alkyl, -C(=O)-OR, -CF₃, -CN, methoxy, ethoxy, fluoro and chloro;

Ar is selected from phenyl and five or six-membered C₃₋₅heteroaryl, wherein said phenyl and five or six-membered C₃₋₅heteroaryl are optionally substituted with one or more groups selected from C₁₋₃alkyl, -C(=O)-OR, -CF₃, -CN, methoxy, ethoxy, fluoro and chloro; and

R is C₁₋₃alkyl.

3. A compound according to claim 1, wherein n is 1 or 2;

R¹ is selected from -CH₂-R⁸, -C(=O)-NH-R⁷, -C(=S)-NH-R⁷, -S(=O)₂-R⁶, and -C(=O)-R⁵, wherein R⁵, R⁶, R⁷ and R⁸ are independantly selected from C₁₋₆alkyl,

C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, phenyl, benzyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, phenyl, benzyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₂alkyl, C₃₋₆heteroaryl are optionally substituted with one or more groups selected from methyl, ethyl, -C(=O)-CH₃, -C(=O)-OCH₃, -C(=O)-OCH₂-CH₃, -SCH₃, -CN, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with -O-CH₂-O- to form a fused ring;

R² is selected from -H, methyl and ethyl;

R³ and R⁴ are independently selected from -H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl,

thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, pyridyl, furyl and thienyl, wherein said phenyl, pyridyl, furyl and thienyl are optionally substituted with one or more methoxy or ethoxy.

4. A compound according to claim 1,

wherein n is 1 or 2;

R^1 is selected from $-\text{CH}_2-\text{R}^8$, $-\text{C}(=\text{O})-\text{NH}-\text{R}^7$, $-\text{C}(=\text{S})-\text{NH}-\text{R}^7$, $-\text{S}(=\text{O})_2-\text{R}^6$, and $-\text{C}(=\text{O})-\text{R}^5$, wherein R^5 , R^6 , R^7 and R^8 are independantly selected from methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl, wherein said methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl are optionally substituted with one or more groups selected from methyl, ethyl, $-\text{C}(=\text{O})-\text{CH}_3$, $-\text{C}(=\text{O})-\text{OCH}_3$, $-\text{C}(=\text{O})-\text{OCH}_2-\text{CH}_3$, $-\text{SCH}_3$, $-\text{CN}$, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with $-\text{O}-\text{CH}_2-\text{O}-$ to form a fused ring;

R^2 is selected from $-\text{H}$, methyl and ethyl;

R^3 and R^4 are independently selected from -H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, 4-ethoxyphenyl, 4-methoxyphenyl, pyridyl, furyl and thienyl.

15

5. A compound according to claim 1, wherein the compound is selected from:

1-Benzoyl-4-phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline;

20

1-Benzoyl-N-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

N,N-Diethyl-4-phenyl-1-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

1-Benzyl-N-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

25

N-[2-(Diethylamino)ethyl]-1-(2-furylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

N-[2-(Diethylamino)ethyl]-4-phenyl-1-(pyridin-3-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

30

N-[2-(Diethylamino)ethyl]-1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinoline-8-carboxamide;

1-(3-Furylmethyl)-8-(morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N-[2-(Diisopropylamino)ethyl]-1-[(5-ethyl-2-furyl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

5 4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-1-(thien-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N,N-Diethyl-4-phenyl-1-(thien-2-ylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

and pharmaceutically acceptable salts thereof.

10

6. A compound according to any one of claims 1-5 for use as a medicament.

7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain, anxiety or functional gastrointestinal


15 disorders.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.


20 9. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

10. A method for the therapy of functional gastrointestinal disorders in a warm-
25 blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

11. A process for preparing a compound of formula I, comprising:



reacting a compound of formula II with a compound selected from $R^5-C(=O)-Cl$, $R^6-S(=O)_2-Cl$, R^7-NCO , R^7-NCS and R^8CHO :



5

wherein

n is 1 or 2;

R^1 is selected from $-CH_2-R^8$, $-C(=O)-NH-R^7$, $-C(=S)-NH-R^7$, $-S(=O)_2-R^6$, and $-C(=O)-R^5$, wherein R^5 , R^6 , R^7 and R^8 are independently selected from C_{1-6} alkyl,

10 C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heteroaryl, and

C_{3-6} heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl,

C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-}

6heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heteroaryl, and C_{3-6} heteroaryl- C_{1-4} alkyl are optionally

15 substituted with one or more groups selected from $-OH$, $-CHO$, $-NH_2$, $-NHR$, $-NR_2$,

C_{1-6} alkyl, $-C(=O)-R$, $-C(=O)-OR$, $-C(=O)-NHR$, $-SR$, $-SH$, halogenated C_{1-6} alkyl,

$-CN$, $-NO_2$, C_{1-6} alkoxy and halogen, or disubstituted with $-O-CH_2-O-$ to form a fused ring;

R^2 is selected from $-H$ and C_{1-6} alkyl;

20 R^3 and R^4 are independently selected from $-H$, C_{1-6} alkyl, C_{2-6} alkenyl,

C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkyl,


C_{3-6} heterocycloalkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heteroaryl, and

C₃₋₆heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy and halogen; or R³ and R⁴ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen;


Ar is selected from C₆₋₁₀aryl and C₃₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₃₋₆heteroaryl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen; and

R is C₁₋₆alkyl.

12. A process for preparing a compound of formula I, comprising:



reacting a compound of formula III with R³R⁴NH:



III

wherein

n is 1 or 2;

R¹ is selected from -C(=O)-O-C₁₋₆alkyl and -C(=O)-O-C₂₋₆alkenyl;


R² is selected from -H and C₁₋₆alkyl;

R³ and R⁴ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy and halogen; or R³ and R⁴ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen;

Ar is selected from C₆₋₁₀aryl and C₃₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₃₋₆heteroaryl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen; and


R is C₁₋₆alkyl.

13. A process for preparing a compound of formula IV, comprising:



IV

reacting a compound of formula V with a compound of formula VI:



wherein

5 n is 1 or 2;

R^1 is selected from $-C(=O)-O-C_{1-6}\text{alkyl}$ and $-C(=O)-O-C_{2-6}\text{alkenyl}$;

R^9 is $C_{1-6}\text{alkyl}$;


Ar is selected from $C_{6-10}\text{aryl}$ and $C_{3-6}\text{heteroaryl}$, wherein said $C_{6-10}\text{aryl}$ and $C_{3-6}\text{heteroaryl}$ are optionally substituted with one or more groups selected from $-OH$,

10 $-CHO$, $-NH_2$, $-NHR$, $-NR_2$, $C_{1-6}\text{alkyl}$, $-C(=O)-OR$, $-C(=O)-NHR$, $-SR$, $-SH$,

halogenated $C_{1-6}\text{alkyl}$, $-CN$, $-NO_2$, $C_{1-6}\text{alkoxy}$, and halogen; and

R is $C_{1-6}\text{alkyl}$.

14. A compound of formula II:



wherein

n is 1 or 2;

R^2 is selected from $-H$ and $C_{1-6}\text{alkyl}$;

20 R^3 and R^4 are independently selected from $-H$, $C_{1-6}\text{alkyl}$, $C_{2-6}\text{alkenyl}$,

$C_{3-6}\text{cycloalkyl}$, $C_{3-6}\text{cycloalkyl}-C_{1-4}\text{alkyl}$, $C_{6-10}\text{aryl}$, $C_{6-10}\text{aryl}-C_{1-4}\text{alkyl}$,

$C_{3-6}\text{heterocycloalkyl}$, $C_{3-6}\text{heterocycloalkyl}-C_{1-4}\text{alkyl}$, $C_{3-6}\text{heteroaryl}$, and

$C_{3-6}\text{heteroaryl}-C_{1-4}\text{alkyl}$, wherein said $C_{1-6}\text{alkyl}$, $C_{2-6}\text{alkenyl}$, $C_{3-6}\text{cycloalkyl}$,

C₃₋₆cycloalkyl-C₁₋₄alkyl, C₆₋₁₀aryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heteroaryl, and C₃₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy and halogen; or R³ and R⁴ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen;

Ar is selected from C₆₋₁₀aryl and C₃₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₃₋₆heteroaryl are optionally substituted with one or more groups selected from -OH, -CHO, -NH₂, -NHR, -NR₂, C₁₋₆alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C₁₋₆alkyl, -CN, -NO₂, C₁₋₆alkoxy, and halogen; and

R is C₁₋₆alkyl.

15. A compound according to claim 14, wherein the compound is selected from:

8-[(4-Methylpiperazin-1-yl)carbonyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-Phenyl-*N*-(tetrahydrofuran-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

- N,N*-Diethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- 4-(4-Ethoxyphenyl)-8-[(4-methylpiperazin-1-yl)carbonyl]-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
- 5 4-(4-Ethoxyphenyl)-8-(morpholin-4-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
- 4-(4-Ethoxyphenyl)-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
- N*-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- 10 4-(4-Ethoxyphenyl)-*N*-(2-furylmethyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- N*-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- 15 *N*-[2-(Diethylamino)ethyl]-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- (4-(4-Ethoxyphenyl)-*N,N*-diethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- N*-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
- 20 Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-4-methyl-;
- Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;
- 25 Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;
- 30

- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-
2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-
2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;
- 5 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(4-
methoxyphenyl)-*N*-(2-pyridinylmethyl)-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-(2-
pyridinylmethyl)-;
- 10 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-
N-(2-pyridinylmethyl)-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-
hexahydro-4-(2-pyridinyl)-;
- 1-Piperazinecarboxaldehyde, 4-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-
c]quinolin-8-yl)carbonyl]-;
- 15 1-Piperazinecarboxaldehyde, 4-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-
pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-;
- Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-
yl)carbonyl]-4-(phenylmethyl)-;
- Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-
yl]carbonyl]-4-(phenylmethyl)-;
- 20 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-
2,3,3a,4,5,9b-hexahydro-4-phenyl-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-
2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
- 25 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-
2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-
2,3,3a,4,5,9b-hexahydro-4-phenyl-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-
hexahydro-*N*-methyl-4-phenyl-;
- 30

- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-*N*-methyl-4-(2-pyridinyl)-;
- 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-[2-(4-thiomorpholinyl)ethyl]-;
- 5 1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-*N*-[2-(4-thiomorpholinyl)ethyl]-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-5-(4-ethoxyphenyl)-
- 10 1,2,3,4,4a,5,6,10b-octahydro-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-thienylmethyl)-;
- 15 Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-*N,N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-
- 20 octahydro-*N*-[2-(1-pyrrolidinyl)ethyl]-;
- Pyrrolidine, 1-[(1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;
- 25 Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
- Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-
- 30 *N*-(2-thienylmethyl)-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N,N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

5 Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-*N*-[2-(1-pyrrolidinyl)ethyl]-;

Pyrrolidine, 1-[(6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;

10 Benzo[*h*][1,6]naphthyridine-9-carboxamide, 6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

N-Cyclopropyl-6-ethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

15 6-Ethyl-5-phenyl-*N*-(thien-2-ylmethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

6-Ethyl-*N*-[(5-methyl-2-furyl)methyl]-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

20 *N,N*,6-Triethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

6-Ethyl-5-phenyl-*N*-(2-pyrrolidin-1-ylethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

4-(4-Ethoxyphenyl)-*N,N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

25 4-(4-Ethoxyphenyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

30 *N*-Cyclobutyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Cyclopropyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Allyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

5 4-(4-Ethoxyphenyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

10 *N,N*-Dimethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Methyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

15 *N*-Cyclobutyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Cyclopropyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

20 (*N*-Allyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-Phenyl-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

25 4-(2-Furyl)-*N,N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(2-Furyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

30 *N*-(Cyclopropylmethyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Cyclobutyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Cyclopropyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

5 *N*-Allyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(2-Furyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

10 8-(Azetidin-1-ylcarbonyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N,N-Dimethyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Methyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

15 *N*-(Cyclopropylmethyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Cyclobutyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

20 *N*-Cyclopropyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-Allyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

8-(Piperidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

25 8-(Azetidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N-[2-(Dimethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide; and pharmaceutically acceptable salts thereof.